Lumos Diagnostics Secures Follow-On Contract to Manage Study to Advance In-Home Phenylketonuria Monitoring Device to Support US FDA Clearance

MT Newswires Live

01/19

Lumos Diagnostics Holdings (ASX:LDX) secured a follow-on contract with Aptatek Biosciences to manage the institutional review board-approved multi-center study to advance an in-home monitoring tool for the screening and management of phenylketonuria to support clearance from the US Food and Drug Administration, according to a Monday Australian bourse filing.

Lumos will provide clinical study support services, from startup through to close-out, including compilation and statistical analysis of the results and generation of the clinical study report for submission to the US FDA. The study is expected to start in the second quarter and run for around six months.

This new contract is valued at around $400,000, which will be charged on a time-and-materials basis.

The firm's shares rose 2% in recent trading on Monday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2604903283"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2604903283\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2604903283?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-19 09:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604903283","market":"nz","top_or_hot":-1,"title":"Lumos Diagnostics Secures Follow-On Contract to Manage Study to Advance In-Home Phenylketonuria Monitoring Device to Support US FDA Clearance","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> Holdings (ASX:LDX) secured a follow-on contract with Aptatek Biosciences to manage the institutional review board-approved multi-center study to advance an in-home monitoring tool for the screening and management of phenylketonuria to support clearance from the US Food and Drug Administration, according to a Monday Australian bourse filing.</p><p>Lumos will provide clinical study support services, from startup through to close-out, including compilation and statistical analysis of the results and generation of the clinical study report for submission to the US FDA. The study is expected to start in the second quarter and run for around six months.</p><p>This new contract is valued at around $400,000, which will be charged on a time-and-materials basis.</p><p>The firm's shares rose 2% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lumos Diagnostics Secures Follow-On Contract to Manage Study to Advance In-Home Phenylketonuria Monitoring Device to Support US FDA Clearance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLumos Diagnostics Secures Follow-On Contract to Manage Study to Advance In-Home Phenylketonuria Monitoring Device to Support US FDA Clearance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-19 09:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> Holdings (ASX:LDX) secured a follow-on contract with Aptatek Biosciences to manage the institutional review board-approved multi-center study to advance an in-home monitoring tool for the screening and management of phenylketonuria to support clearance from the US Food and Drug Administration, according to a Monday Australian bourse filing.</p><p>Lumos will provide clinical study support services, from startup through to close-out, including compilation and statistical analysis of the results and generation of the clinical study report for submission to the US FDA. The study is expected to start in the second quarter and run for around six months.</p><p>This new contract is valued at around $400,000, which will be charged on a time-and-materials basis.</p><p>The firm's shares rose 2% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7126","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2604903283","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604903283","pubTimestamp":1768785015,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lumos Diagnostics Holdings  secured a follow-on contract with Aptatek Biosciences to manage the institutional review board-approved multi-center study to advance an in-home monitoring tool for the screening and management of phenylketonuria to support clearance from the US Food and Drug Administration, according to a Monday Australian bourse filing.Lumos will provide clinical study support services, from startup through to close-out, including compilation and statistical analysis of the results and generation of the clinical study report for submission to the US FDA. The study is expected to start in the second quarter and run for around six months.This new contract is valued at around $400,000, which will be charged on a time-and-materials basis.The firm's shares rose 2% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7126":"医疗保健用品","LDX.AU":"LUMOS DIAGNOSTICS HOLDINGS L","BK4195":"互助储蓄与抵押信贷金融服务","HBCP":"Home Bancorp Inc","BK4211":"区域性银行"},"translate_title":"Lumos Diagnostics获得后续合同，管理改进家用苯丙酮尿症监测设备的研究，以支持美国FDA的批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LDX.AU":1,"HBCP":1.5},"content_text":"Lumos Diagnostics Holdings (ASX:LDX) secured a follow-on contract with Aptatek Biosciences to manage the institutional review board-approved multi-center study to advance an in-home monitoring tool for the screening and management of phenylketonuria to support clearance from the US Food and Drug Administration, according to a Monday Australian bourse filing.Lumos will provide clinical study support services, from startup through to close-out, including compilation and statistical analysis of the results and generation of the clinical study report for submission to the US FDA. The study is expected to start in the second quarter and run for around six months.This new contract is valued at around $400,000, which will be charged on a time-and-materials basis.The firm's shares rose 2% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}